Mechanisms of coronary endothelial dysfunction in diabetes

糖尿病冠状动脉内皮功能障碍的机制

基本信息

  • 批准号:
    7787083
  • 负责人:
  • 金额:
    $ 1.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-01 至 2010-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cardiovascular complications account for significant morbidity and mortality in diabetic patients. Diabetic coronary vascular disease has been recognized as a risk factor that may lead to heart failure. Endothelial cells play a major role in the maintenance of vascular tone and revascularization, while an endothelial dysfunction is commonly observed in diabetes. Gap junctions, formed by connexins (Cxs), provide important pathways for the cell-cell communication and Cx40 is known to be specially important in pathogenesis of hypertension and hyperlipidemia. It is, however, unclear whether Cx40 contributes to the development of coronary vascular complication in diabetes. The object of this application is to investigate the role of Cx40 in coronary endothelial dysfunction using diabetic mice. The hypothesis of this study is that chronic exposure of endothelial cells to hyperglycemia results in downregulated Cx40 protein expression, which increases coronary vascular resistance, decreases cardiac blood supply and increases mortality in diabetes. Three specific aims are proposed to test the hypothesis: 1) To examine whether exposure of coronary endothelial cells to hyperglycemia decreases capillary density and inhibits vascular function through downregulation of Cx40 protein expression; 2) To test whether overexpression of Cx40 gene in endothelial cells serves as a therapeutic approach for coronary endothelial dysfunction in diabetic mice; and 3) To determine whether Cx40 function in diabetes is controlled by enzymatic 0-linked glycosylation of Cx40's transcription factors and Cx40 itself. My long-term goal is to identify the mechanisms for diabetic coronary vascular dysfunction and to develop endothelial cell-based therapeutic strategies to reduce or prevent the progression of coronary vascular disease. To work under a mentorship of Dr. Wolfgang Dillmann provides a great opportunity to learn how to generate endothelial cell-based transgenic mouse model to investigate Cx40 function at the molecular level in diabetes. The purpose of this award is to obtain support for my independent research project and to facilitate my transition to become a fully independent investigator conducting basic and translational research in the field of cardiovascular pathophysiology. PUBLIC HEALTH RELEVANCE: Completion of this study will provide important insights into developing new therapeutic interventions for coronary vascular decease in diabetes.
描述(由申请人提供): 心血管并发症是糖尿病患者发病率和死亡率的重要原因。糖尿病冠脉病变已被公认为可能导致心力衰竭的危险因素。内皮细胞在维持血管张力和血运重建中起主要作用,而内皮功能障碍在糖尿病中也很常见。缝隙连接蛋白(Cxs)是细胞间通讯的重要途径,Cx40在高血压和高脂血症的发病机制中起着特别重要的作用。然而,目前尚不清楚Cx40是否与糖尿病冠状动脉血管并发症的发生有关。本应用的目的是研究Cx40在糖尿病小鼠冠状动脉内皮细胞功能障碍中的作用。这项研究的假设是,血管内皮细胞长期暴露于高血糖导致Cx40蛋白表达下调,从而增加冠状动脉血管阻力,减少心脏供血,增加糖尿病患者的死亡率。为了验证这一假说,我们提出了三个具体的目标:1)检测冠状动脉内皮细胞暴露于高血糖是否通过下调Cx40蛋白的表达来降低毛细血管密度和抑制血管功能;2)检测内皮细胞中Cx40基因的过表达是否可作为糖尿病小鼠冠状动脉内皮功能障碍的治疗方法;以及3)确定Cx40在糖尿病中的功能是否受Cx40‘S转录因子和Cx40本身的酶促0-连接糖基化调控。我的长期目标是确定糖尿病冠状动脉血管功能障碍的机制,并开发基于内皮细胞的治疗策略,以减少或防止冠状动脉血管疾病的进展。在沃尔夫冈·迪尔曼博士的指导下工作,为学习如何建立基于内皮细胞的转基因小鼠模型,在分子水平上研究Cx40在糖尿病中的功能提供了一个很好的机会。该奖项的目的是为我的独立研究项目获得支持,并促进我过渡为一名完全独立的研究员,在心血管病理生理学领域进行基础和转化性研究。 公共卫生相关性:这项研究的完成将为开发糖尿病冠状动脉血管病变的新治疗干预措施提供重要的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ayako Makino其他文献

Ayako Makino的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ayako Makino', 18)}}的其他基金

Role of Gap Junction in Hypoxia-induced Pulmonary Hypertension
间隙连接在缺氧引起的肺动脉高压中的作用
  • 批准号:
    10394375
  • 财政年份:
    2019
  • 资助金额:
    $ 1.97万
  • 项目类别:
Role of Gap Junction in Hypoxia-induced Pulmonary Hypertension
间隙连接在缺氧引起的肺动脉高压中的作用
  • 批准号:
    10120518
  • 财政年份:
    2019
  • 资助金额:
    $ 1.97万
  • 项目类别:
Cellular and Molecular Mechanisms of Coronary Endothelial Dysfunction in Diabetes
糖尿病冠状动脉内皮功能障碍的细胞和分子机制
  • 批准号:
    8688345
  • 财政年份:
    2012
  • 资助金额:
    $ 1.97万
  • 项目类别:
Cellular and Molecular Mechanisms of Coronary Endothelial Dysfunction in Diabetes
糖尿病冠状动脉内皮功能障碍的细胞和分子机制
  • 批准号:
    8370263
  • 财政年份:
    2012
  • 资助金额:
    $ 1.97万
  • 项目类别:
Cellular and Molecular Mechanisms of Coronary Endothelial Dysfunction in Diabetes
糖尿病冠状动脉内皮功能障碍的细胞和分子机制
  • 批准号:
    8883693
  • 财政年份:
    2012
  • 资助金额:
    $ 1.97万
  • 项目类别:
Cellular and Molecular Mechanisms of Coronary Endothelial Dysfunction in Diabetes
糖尿病冠状动脉内皮功能障碍的细胞和分子机制
  • 批准号:
    8504541
  • 财政年份:
    2012
  • 资助金额:
    $ 1.97万
  • 项目类别:
Mechanisms of coronary endothelial dysfunction in diabetes
糖尿病冠状动脉内皮功能障碍的机制
  • 批准号:
    8227960
  • 财政年份:
    2009
  • 资助金额:
    $ 1.97万
  • 项目类别:
Mechanisms of coronary endothelial dysfunction in diabetes
糖尿病冠状动脉内皮功能障碍的机制
  • 批准号:
    8138788
  • 财政年份:
    2009
  • 资助金额:
    $ 1.97万
  • 项目类别:
Mechanisms of coronary endothelial dysfunction in diabetes
糖尿病冠状动脉内皮功能障碍的机制
  • 批准号:
    7643571
  • 财政年份:
    2009
  • 资助金额:
    $ 1.97万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 1.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 1.97万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 1.97万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 1.97万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 1.97万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 1.97万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 1.97万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 1.97万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 1.97万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 1.97万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了